Chimeric antigen receptors (CARs) are synthesized membrane proteins that enable lymphocytes to recognize and respond to the specific antigens of target cells. Despite the impressive efficacy of CAR-T cell therapy in treating B-cell lymphoma or leukemia, the expensive and complex manufacturing process has hindered its widespread clinical application.